Skip to content

Daniel Hell

7 papers in the library · 2,236 citations · publishing 1998-2006

Papers

Sort Most recent Most cited

Effects of psilocybin on time perception and temporal control of behaviour in humans

Journal of Psychopharmacology May 20, 2006 Marc Wittmann, Olivia Carter, Felix Hasler et al. 245 citations

Hallucinogenic psilocybin is known to alter the subjective experience of time. However, there is no study that systematically investigated objective measures of time perception under psilocybin. Therefore, we studied dose-dependent effects of the serotonin (5-HT) 2A/1A receptor agonist psilocybin (4-phosphoryloxy-N, N-dimethyltryptamine) on temporal processing, employing tasks of temporal...

Modulating the Rate and Rhythmicity of Perceptual Rivalry Alternations with the Mixed 5-HT2A and 5-HT1A Agonist Psilocybin

Neuropsychopharmacology January 26, 2005 Olivia Carter, John D. Pettigrew, Felix Hasler et al. 122 citations

Binocular rivalry occurs when different images are presented simultaneously to corresponding points within the left and right eyes. Under these conditions, the observer's perception will alternate between the two perceptual alternatives. Motivated by the reported link between the rate of perceptual alternations, symptoms of psychosis and an incidental observation that the rhythmicity of...

Localization of MDMA‐induced brain activity in healthy volunteers using low resolution brain electromagnetic tomography (LORETA)

Human Brain Mapping August 27, 2001 Edi Frei, Alex Gamma, Roberto D Pascual-Marqui et al. 175 citations

Abstract 3,4‐Methylenedioxymethamphetamine (MDMA; 'Ecstasy') is a psychostimulant drug producing heightened mood and facilitated social communication. In animal studies, MDMA effects are primarily mediated by serotonin (5‐HT), but also by dopamine (DA) and possibly noradrenaline (NA). In humans, however, the neurochemical and neurophysiological basis of acute MDMA effects remains unknown. The...

Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers

Archives of General Psychiatry December 1, 2000 Daniel Umbricht, Liselotte Schmid, Rene Koller et al. 590 citations

BACKGROUND: In patients with schizophrenia, deficient generation of mismatch negativity (MMN)-an event-related potential (ERP) indexing auditory sensory ("echoic") memory-and a selective increase of "context dependent" ("BX") errors in the "A-X" version of the Continuous Performance Test (AX-CPT) indicate an impaired ability to form and use transient memory traces. Animal and human studies...

Mood state and brain electric activity in Ecstasy users

Neuroreport 2000 Alex Gamma, Edi Frei, Dietrich Lehmann et al. 81 citations

Resting EEG during open and closed eyes and subsequent mood ratings were obtained from 15 Ecstasy users and 14 Ecstasy-naive controls. Absolute spectral power on the scalp, and the three-dimensional, intracerebral distribution of neuroelectric activity using low resolution brain electromagnetic tomography (LORETA) were computed. LORETA revealed global increases of theta, alpha 1 and beta 2/3...

5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology May 1999 F X Vollenweider, P Vontobel, D Hell et al.

The modulating effects of serotonin on dopamine neurotransmission are not well understood, particularly in acute psychotic states. Positron emission tomography was used to examine the effect of psilocybin on the in vivo binding of [11C]raclopride to D2-dopamine receptors in the striatum in healthy volunteers after placebo and a psychotomimetic dose of psilocybin (n = 7). Psilocybin is a potent...

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

Neuroreport December 1, 1998 Franz X. Vollenweider, M. F. I. Vollenweider-Scherpenhuyzen, Andreas Bäbler et al. 1,023 citations

Psilocybin, an indoleamine hallucinogen, produces a psychosis-like syndrome in humans that resembles first episodes of schizophrenia. In healthy human volunteers, the psychotomimetic effects of psilocybin were blocked dose-dependently by the serotonin-2A antagonist ketanserin or the atypical antipsychotic risperidone, but were increased by the dopamine antagonist and typical antipsychotic...